First Time Loading...
C

Clarus Therapeutics Holdings Inc
NASDAQ:CRXT

Watchlist Manager
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Watchlist
Price: 0.021 USD -19.54% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

CRXT price has not been updated for more than 2 months. This may indicate that the stock has been delisted.
CRXT doesn't have a meaningful market cap.

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of CRXT.

Key Points:
CRXT Intrinsic Value
Base Case
Not Available
C
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Clarus Therapeutics Holdings Inc's business.

What risks and challenges
does Clarus Therapeutics Holdings Inc face in the near future?

Summarize the latest earnings report
of Clarus Therapeutics Holdings Inc.

Provide P/E
for Clarus Therapeutics Holdings Inc and its competitors.

Financials

Balance Sheet Decomposition
Clarus Therapeutics Holdings Inc

Current Assets 48.9m
Cash & Short-Term Investments 19.2m
Receivables 8.7m
Other Current Assets 21m
Non-Current Assets 60k
PP&E 60k
Current Liabilities 61.8m
Accounts Payable 8.5m
Accrued Liabilities 9.8m
Other Current Liabilities 43.5m
Non-Current Liabilities 197k
Other Non-Current Liabilities 197k
Efficiency

Earnings Waterfall
Clarus Therapeutics Holdings Inc

Revenue
16.9m USD
Cost of Revenue
-3.6m USD
Gross Profit
13.3m USD
Operating Expenses
-53.2m USD
Operating Income
-39.9m USD
Other Expenses
7.3m USD
Net Income
-32.6m USD

Free Cash Flow Analysis
Clarus Therapeutics Holdings Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CRXT Profitability Score
Profitability Due Diligence

Clarus Therapeutics Holdings Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional ROE
Exceptional 1-Year Revenue Growth
Positive Gross Profit
37/100
Profitability
Score

Clarus Therapeutics Holdings Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

CRXT Solvency Score
Solvency Due Diligence

Clarus Therapeutics Holdings Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
32/100
Solvency
Score

Clarus Therapeutics Holdings Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRXT Price Targets Summary
Clarus Therapeutics Holdings Inc

There are no price targets for CRXT.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CRXT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CRXT Price
Clarus Therapeutics Holdings Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
-100%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
0.021
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return
N/A
Standard Deviation of Annual Returns
N/A
Max Drawdown -100%
Shares Statistics
Market Capitalization 1.1m USD
Shares Outstanding 52 020 700
Percentage of Shares Shorted 6.89%

CRXT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Clarus Therapeutics Holdings Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1.1m USD

Dividend Yield

0%

Description

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Northbrook, Illinois and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is focused on the commercialization of JATENZO, an oral T-replacement, or T-replacement therapy (TRT). The Company’s lead product, JATENZO, an androgen indicated for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. In addition, JATENZO focuses on the classic signs and symptoms associated with hypogonadism, including psychosexual symptoms, body mass index, fat mass and bone mineral density. The firm plans to focused on the development and commercialization of T and metabolic therapies for men and women.

Contact

ILLINOIS
Northbrook
555 Skokie Boulevard, Suite 340
+16463030737.0
https://clarustherapeutics.com/

IPO

2020-12-17

Employees

16

Officers

Founder, Pres, CEO & Director
Dr. Robert E. Dudley Ph.D.
Chief Financial Officer
Mr. Richard Dale Peterson
Chief Commercial Officer
Mr. Frank A. Jaeger M.A., M.B.A.
VP of Commercial Analytics & Operations
Mr. Steve Stark
Chief Admin. Officer, Sec. & Treasurer
Mr. Steven A. Bourne CPA
VP of Investor Relations & Corp. Communications
Ms. Kara J. Stancell
Show More
VP of Marketing
Ms. Rozita Passarella
VP of Sales
Mr. Mike Cleveland
Chief Medical Officer
Dr. Jay Newmark M.B.A., M.D.
Sr. VP of Manufacturing & Supply
Mr. James Holloway
Show Less

See Also

Discover More